SEC Tracker
Get the app

Femasys FEMY

Femasys FY 2021: revenue $1.2M; diluted EPS −$22.40

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Femasys reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$1.2MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$7.5MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$22.40No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$1.1210-K income statement, on EDGAR
  4. Cash and cash equivalents$24.8MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  5. Cash from operations−$7.9MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Femasys files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. DarioHealth DRIO public float $28M, Jun 30, 2025
  2. Cerenome CNSY public float $32M, Jun 30, 2025
  3. electroCore ECOR public float $28M, Jun 30, 2025
  4. QT Imaging Holdings QTI public float $33M, Jun 30, 2025
  5. Nephros NEPH public float $27M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.